Abstract
A series of symmetrical Schiff base derivatives (L1-L7) were designed by a one-pot condensation reaction of various aldehyde/ketone compounds with hydrazine under mild conditions (room temperature, 3 days), using ether as solvent and acetic acid as catalyst. The target products were characterized and analysed by 1H and 13C NMR, FT-IR and liquid chromatography mass spectrometry (LC/MS). Our research focuses on the identification of synthetically chemotherapeutic substances able to inhibit, delay, or reverse the process of carcinogenesis in several stages. The target compounds presenting two regions for SAR evaluation were screened for their activity toward MDA-MB-241 breast cancer cell proliferation for the first time. Compound (1E, 2E)-1,2-bis(1-(3-nitrophenyl)ethylidene) hydrazine (L6) showed significant inhibitory activity (IC50 = 7.08 µg/mL).
Keywords: Schiff bases, heterocycles, nitro, antitumor activity, breast cancer, cell proliferation.
Letters in Drug Design & Discovery
Title:Synthesis and Evaluation of Certain Symmetrical Schiff Bases as Inhibitors of MDA-MB-241 Human Breast Cancer Cell Proliferation
Volume: 13 Issue: 3
Author(s): Smaail Radi, Said Tighadouini, Olivier Feron, Olivier Riant and Yahia N. Mabkhot
Affiliation:
Keywords: Schiff bases, heterocycles, nitro, antitumor activity, breast cancer, cell proliferation.
Abstract: A series of symmetrical Schiff base derivatives (L1-L7) were designed by a one-pot condensation reaction of various aldehyde/ketone compounds with hydrazine under mild conditions (room temperature, 3 days), using ether as solvent and acetic acid as catalyst. The target products were characterized and analysed by 1H and 13C NMR, FT-IR and liquid chromatography mass spectrometry (LC/MS). Our research focuses on the identification of synthetically chemotherapeutic substances able to inhibit, delay, or reverse the process of carcinogenesis in several stages. The target compounds presenting two regions for SAR evaluation were screened for their activity toward MDA-MB-241 breast cancer cell proliferation for the first time. Compound (1E, 2E)-1,2-bis(1-(3-nitrophenyl)ethylidene) hydrazine (L6) showed significant inhibitory activity (IC50 = 7.08 µg/mL).
Export Options
About this article
Cite this article as:
Radi Smaail, Tighadouini Said, Feron Olivier, Riant Olivier and Mabkhot N. Yahia, Synthesis and Evaluation of Certain Symmetrical Schiff Bases as Inhibitors of MDA-MB-241 Human Breast Cancer Cell Proliferation, Letters in Drug Design & Discovery 2016; 13 (3) . https://dx.doi.org/10.2174/1570180812999150812165510
DOI https://dx.doi.org/10.2174/1570180812999150812165510 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
TRPV1 Antagonists as a Potential Treatment for Hyperalgesia
Recent Patents on CNS Drug Discovery (Discontinued) Exploring Proteomic Drug Targets, Therapeutic Strategies and Protein - Protein Interactions in Cancer: Mechanistic View
Current Cancer Drug Targets Apoptotic Potency of Angiostatic Compounds in the Treatment of Cancer
Current Pharmaceutical Biotechnology Porphyrins in Photodynamic Therapy - A Search for Ideal Photosensitizers
Current Medicinal Chemistry - Anti-Cancer Agents MicroRNA Regulation in Cardiovascular Disease
Current Drug Targets Collateral Damage: Contribution of Peripheral Inflammation to Neurodegenerative Diseases
Current Topics in Medicinal Chemistry The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson's Disease Model
CNS & Neurological Disorders - Drug Targets Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly
Current Pharmaceutical Design Inhibitors of the Immunoproteasome: Current Status and Future Directions
Current Pharmaceutical Design CXCR4-CXCL12-Dependent Inflammatory Network and Endothelial Progenitors
Current Medicinal Chemistry Methylenetetrahydrofolate Reductase (MTHFR): A Novel Target for Cancer Therapy
Current Pharmaceutical Design Emerging Restorative Treatments for Parkinsons Disease: Manipulation and Inducement of Dopaminergic Neurons from Adult Stem Cells
CNS & Neurological Disorders - Drug Targets Preface
Current Pharmaceutical Design Stimuli-responsive Carriers for Controlled Intracellular Drug Release
Current Medicinal Chemistry Outline of Proteins and Signaling Pathways Involved in Heart Failure
Current Protein & Peptide Science Natural Sesquiterpenoids as Cytotoxic Anticancer Agents
Mini-Reviews in Medicinal Chemistry C-11 Radiochemistry in Cancer Imaging Applications
Current Topics in Medicinal Chemistry Fibrates in the Chemical Action of Daunorubicin
Current Cancer Drug Targets Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Current Cancer Drug Targets Contributions of the Interaction Between Dietary Protein and Gut Microbiota to Intestinal Health
Current Protein & Peptide Science